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Abstract
Background:  Gut  microbiota  may  play  a  role  in  non-alcoholic  steatohepatitis  (NASH).  Previous
studies showed  that  prebiotics  and  probiotics  might  halt  the  progression  of  steatohepatitis.
Aim: To  clarify  the  potential  effect  of  Synbiotic  2000®Forte  (Synb)  in  preventing  or  ameliorat-
ing diet  induced  steatohepatitis,  particularly  in  ﬁbrosis  progression  and  how  this  intervention
correlates  with  gut  microbiota  composition  and  endotoxinemia.
Methods:  Twenty-seven  C57BL/6  mice  were  divided  into  three  groups:  chow  diet  (CD,  n  =  7);
high-fat choline  deﬁcient  diet  (HFCD,  n  =  10)  and  HFCD  diet  supplemented  with  Synbiotic
2000®Forte  (four  probiotic  strains  and  four  prebiotics  mixture)  (HFCD  +  Synb,  n  =  10).  At  6  and
18 weeks,  blood  samples  (lipopolysaccharides  assay  --  LPS),  cecal  feaces  (gut  microbiota)  and
liver tissue  (histology)  were  collected  for  analysis.
Results:  Both  HCFD  diet  mice  developed  steatohepatitis  with  ballooning  at  6  and  18  weeks,
opposite  to  CD.  Comparison  of  histological  scores  in  HFCD  and  HFCD  +  Synb,  at  6  and  18  weeks
showed no  signiﬁcant  difference  regarding  steatosis,  inﬂammation,  or  ballooning.  Evaluating
ﬁbrosis with  Sirius  Red,  and  degree  of  smooth-muscle  cell  activation,  HFCD  mice  had  signiﬁ-
cantly more  ﬁbrosis;  addition  of  Synb  signiﬁcantly  reduced  ﬁbrosis  at  6  weeks  and  18  weeks.
Serum endotoxin  levels  were  similarly  increased  in  HFCD  and  HFCD  +  Synb  at  week  6;  however
at week  18  HFCD  +  Synb  had  signiﬁcantly  lower  endotoxin  levels  than  HFCD.  Gut  microbiotaAbbreviations: NASH, non-alcoholic steatohepatits; Synb, Synbiotic 2000®Forte; CD, control diet; HFCD, high fat choline deﬁcient diet;
PS, lipopolysaccharide; NAFLD, non-alcoholic fatty liver disease; TLR4, toll-like receptor-4.
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of  HFCD  vs  CD,  showed  no  signiﬁcant  differences  regarding  the  phyla  Firmicutes  and  Bac-
teroidetes, either  at  6  or  18  weeks;  Proteobacteria  increased  at  6  week  (3.3)  and  18  week
(7.5), while  the  addition  of  Synb  resulted  in  a  decrease  at  week  18  (−3.90).  Fusobacteria
markedly increase  at  week  18  (10.0),  but  less  so  with  the  addition  of  Synb  (5.2).
Conclusion:  Synbiotic  2000®Forte  is  able  to  modulate  the  mouse  gut  microbiota  reducing  the
degree of  ﬁbrosis  while  simultaneously  decreasing  endotoxemia.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier
España, S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A  Modulac¸ão  da  Microbiota  Com  Simbiótico  Reduz  a  Fibrose  Hepática  num  Modelo  de
Ratinho  Com  Esteatohepatite  (EHNA)  Não  Alcoólica  Induzida  por  Dieta  Gorda  e
Deﬁciente  em  Colina
Resumo
Introduc¸ão: A  microbiota  intestinal  pode  ter  um  papel  na  esteatohepatite  não  alcoólica  (EHNA).
Estudos prévios  mostraram  que  os  prebióticos  e  próbioticos  podem  interromper  a  progressão
da esteatohepatite.
Objetivo:  Clariﬁcar  o  efeito  potencial  do  Synbiotic  2000®Forte  (Synb)  na  prevenc¸ão  ou  melhoria
da esteatohepatite  induzida  pela  dieta,  particularmente  na  progressão  da  ﬁbrose  e  como  essa
intervenc¸ão se  correlaciona  com  a  microbiota  intestinal  e  endotoxinemia.
Métodos:  Vinte  e  sete  ratinhos  C57BL/6  foram  divididos  em  3  grupos:  dieta  de  rac¸ão  (CD,
n =  7);  dieta  gorda  deﬁciente  em  colina  (HFCD,  n  =  10)  e  HFCD  dieta  suplementada  com  Synbiotic
2000®Forte  (4  cepas  de  probioticos  e  mistura  de  4  prebióticos),  (HFCD  +  Synb,  n  =  10).  Às  6  e
18 semanas,  foi  colhido  sangue  para  dosear  o  lipopolisacárido  (LPS);  foram  também  analisadas
fezes do  cego  (microbiota  intestinal)  e  tecido  hepático  (histologia).
Resultados:  Todos  os  ratinhos  sujeitos  a  dieta  HCFD,  desenvolveram  esteatohepatite  com
balonizac¸ão às  6  e  18  semanas,  em  oposic¸ão  aos  CD.  A  comparac¸ão  dos  scores  histológicos
nos HFCD  e  HFCD  +  Synb,  às  6  e  18  semanas  não  revelou  diferenc¸as  signiﬁcativas  em  relac¸ão  à
esteatose, inﬂamac¸ão,  ou  balonizac¸ão.  A  avaliac¸ão  da  ﬁbrose  através  do  Sirius  Red,  e  o  grau
de ativac¸ão  das  células  do  músculo  liso,  revelou  que  os  ratinhos  HFCD  tinham  signiﬁcativa-
mente mais  ﬁbrose;  a  adic¸ão  do  Synb  reduziu  signiﬁcativamente  a  ﬁbrose  às  6  e  18  semanas.
Os níveis  de  endotoxina  sérica  estavam  aumentados  de  forma  semelhante  às  6  semanas  nos
HFCD e  HFCD  +  Synb;  contudo  à  semana  18,  os  HFCD  +  Synb  tinham  signiﬁcativamente  menores
níveis de  endotoxina  em  relac¸ão  aos  HFCD.  A  microbiota  intestinal  dos  HFCD  vs  CD,  não  rev-
elou diferenc¸as  signiﬁcativas  nos  ﬁlos  Firmicutes  e  Bacteroidetes,  quer  às  6  ou  às  18  semanas;
Proteobacteria  aumentou  às  6  semanas  (3.3)  e  18  semanas  (7.5),  enquanto  a  adic¸ão  de  Synb
resultou  numa  reduc¸ão  à  semana  18  (-3.9).  Fusobacteria  aumentou  signiﬁcativamente  à  semana
18 (10.2),  mas  menos  com  a  adic¸ão  de  Synb  (5.8).
Conclusão:  O  Synbiotic  2000®Forte  foi  capaz  de  modular  a  microbiota  intestinal  do  ratinho
reduzindo  o  grau  de  ﬁbrose,  enquanto  simultaneamente  reduziu  a  endotoxemia.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier
España, S.L.U.  Este  é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Non-alcoholic  steatohepatitis  (NASH)  is  a  metabolic  liver  dis-
ease  of  epidemic  importance  in  many  countries,  and  strongly
related  with  the  increased  prevalence  of  obesity  and  fea-
tures  of  the  metabolic  syndrome  in  western  countries.1
It  is  characterized  by  the  association  of  hepatic  steato-
sis  with  liver  cell  injury,  ballooning,  lobular  inﬂammation
and  variable  degrees  of  ﬁbrosis,  that  can  progress  to  end-
stage  cirrhosis.  Clinical  and  experimental  research  suggests
that  the  pathogenesis  of  NASH  involves  a  multifactorial
s
p
aechanism  by  which,  in  the  setting  of  a  fatty  liver,  altered
ipid  metabolism,  dysregulated  cytokine  production  and
xidative  stress  cause  injury  and  provoke  hepatic  inﬂam-
ation  and  ﬁbrosis.2
In  the  last  years,  there  has  been  a  great  interest  in
he  role  that  microbiota  may  play  in  liver  diseases,  par-
icularly  in  non-alcoholic  fatty  liver  disease.3--8 In  fact,
everal  studies  have  highlighted  the  association  between
mall  intestinal  bacterial  overgrowth,  increased  intestinal
ermeability  and  nonalcoholic  steatohepatitis  (NASH),  prob-
bly  due  to  increased  endotoxinaemia  and  activation  of  the
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oll-like  receptor-4  (TLR4)  signalling  cascade;  studies  have
ocused  on  the  possibility  that  activation  of  liver  ﬁbroge-
esis  may  depend  on  the  stimulation  of  stellate  cells  and
upffer  cells  by  TLR4.9--13 An  additional  possible  role  for
icrobiota  in  NAFLD,  is  related  with  the  pathogenesis  of
besity,  since  there  is  evidence  that  some  Gram-anaerobes,
uch  as  Bacteroides  thetaiotaomicron  are  able  to  degrade
lant  polysaccharides,14 thus  increasing  the  caloric  extrac-
ion  from  diet;  also,  colonization  of  the  gut  in  experimental
odels  of  germ-free  mice,  induces  obesity,15 and  in  the
pposite,  microbiota  depletion  promotes  browning  of  white
dipose  tissue  and  reduces  obesity.16 Another  potential
ontribution  of  microbiota  to  NAFLD  relates  to  suppression
f  the  lipoprotein  lipase  (LPL)  inhibitor,  angiopoietin-like  4,
ence  allowing  continued  expression  of  LPL  that  regulates
atty  acid  release  from  triglycerides  in  the  liver.17
Our  aim  was  to  clarify  the  potential  effects  of  the
our  probiotic  strains  and  four  prebiotics  mixture  (Synbi-
tic  2000®Forte)  in  preventing  or  ameliorating  diet  induced
teatohepatitis,  and  particularly  ﬁbrosis  progression.  In
rder  to  get  a  model  more  similar  to  human  NASH  we
ave  chosen  a  moderate  high-fat  diet  (35%)  simultaneously
holine  deﬁcient  (HFCD),  since  it  has  been  shown  that
dding  choline  deﬁciency  to  a  high-fat  diet,  ampliﬁes  liver
at  accumulation.18 We  also  aimed  to  evaluate  how  this
ntervention  correlates  with  microbiota  composition  and
ndotoxinemia.
. Methods
.1.  Animal  housing  and  diet
 total  of  27  pathogen-free  male  C57BL/6  six  week-old  mice
Harlan  Laboratories,  Castellar,  Spain)  weighing  15--20  g
ere  housed  in  individual  cages  and  kept  at  a  temperature
f  22 ◦C,  on  a  12:12  h  light/dark  cycle,  in  the  Portuguese
ational  Institute  of  Health.
Upon  arrival,  the  mice  were  acclimated  for  14  days  prior
o  being  used  in  experiments,  and  had  ad  libitum  access
o  tap  water  and  feeding.  This  study  was  reviewed  and
pproved  by  the  National  Animal  Care  Committee  from
irecc¸ão  Geral  de  Veterinária. All  procedures  with  animals
ere  in  compliance  with  the  Care  and  Use  of  Laboratory
nimals.
Steatohepatitis  was  induced  by  a  high-fat  diet  (35%  total
at,  54%  trans-fatty  acid  enriched)  choline-deﬁcient  --  HFCD
iet,  --Harlan  Laboratories,  Castellar,  Spain  and  Standard
how  diet  was  obtained  from  (Mmucedola  srl  --  4RF21  cer-
iﬁcate  batch:  250202).
.2.  Study  design
fter  acclimatization  period,  mice  were  divided  into  three
ifferent  groups  according  the  type  of  diet  and  product
dministration:  (1)  regular  chow  diet  (CD)  n  =  7;  (2)  high  fat
holine  deﬁcient  diet  (HFCD)  n  =  10;  (3)  HFCD  plus  Synbiotic
000®Forte  (HFCD  +  Synb)  n  =  10.
Using  a  20-gauge  ballpoint  metal  feeding  tube  (Harvard
pparatus,  Inc.,  Holliston,  MA),  mice  were  inoculated  intra-
astric,  three  times/week  with  either  phosphate  buffered
R
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aline  (PBS),  CD  and  HFCD  groups  or  Synbiotic  2000®Forte:
0  mg/mice  (4  ×  108 bacteria/mouse),  HFCD  +  Synb  group.
At  week  6,  ﬁve  mice  of  each  group  were  euthanized.  The
emaining  mice  of  each  group  were  euthanized  at  week  18.
.3.  Bacterial  viability  of  Synbiotic  2000®Forte
ach  sachet  consisted  of  a  combination  of  1011 CFU  of  each  of
our  probiotics:  Lactobacillus  paracasei:  25%,  Lactobacillus
lantarum: 25%,  Leuconostoc  mesenteroides:  25%,  Pedio-
occus  pentosaceus: 25%  with  bioactive  ﬁbres,  total  weight:
0  g,  oat  bran:  2.5  g,  pectin:  2.5  g,  resistant  starch:  2.5  g,
nulin:  2.5  g.
To access  the  viability  of  the  Synbiotic  2000®Forte  mix-
ure,  assays  in  duplicate  were  performed.  After  recovery  of
he  lyophilized,  the  mixture  was  cultured  on  Schaedler  agar
nd  incubated  at  35 ◦C  for  48  h  under  anaerobic  conditions.
olonies  were  tested  for  biochemical  activities  and  moni-
ored  microscopically  by  Gram  stain.  It  was  observed  that
he  viability  of  Lactobacillus  casei  and  L.  plantarum  was
3%,  the  Pediococus  100%  and  the  Leuconostoc  72%.
.4.  Sampling
t  the  time  of  sacriﬁce  by  cervical  dislocation,  after  14  h
asting,  total  body  and  liver  of  each  mice  was  weighed.
lood  was  collected  to  perform  LPS  assay.  Liver  tissue  was
rocessed  for  histology  and  cecal  faeces  were  taken  to  eval-
ate  gut  microbiota.  Serum  and  faeces  were  stored  at  −80 ◦C
ntil  used.
.5.  Blood  analysis
lood  was  collected  and  centrifuged  for  10  min  at  3000  rpm.
erum  samples  were  used  to  perform  LPS  assay  using  the
usabio  Biotech  CO.,  LTD,  Wuhan,  China  according  to  the
anufacturer’s  instruction.
.6.  Histology
n  each  time  point,  liver  mice  was  obtained  and  divided
nto  two  fragments:  one  was  ﬂash-frozen  in  liquid  nitrogen
nd  kept  at  −80 ◦C  until  analysis.  The  tissue  was  homoge-
ized  and  total  proteins  were  extracted  and  isolated.  The
ther  fragment  was  placed  in  a  10%  buffered  formalin  solu-
ion.  The  tissue  was  routinely  processed,  parafﬁn  embedded
nd  sectioned  at  a  thickness  of  4  m.  Haematoxylin--eosin
nd  Sirius  Red  staining  were  performed.  For  the  detec-
ion  of  activated  hepatic  stellate  cells,  -SMA  positive  cells
ere  immunohistochemically  assessed  by  -SMA  antibody.
mmunostaining  was  performed  manually  by  the  peroxidase-
ndirect-polymer  method  (Envision  Dako  --  HRP,  Code  K4011)
or  30  min.  Sections  2  m  thick  were  cut,  unto  Superfrost
lus  slides,  from  parafﬁn-embedded  routine  tissue  blocks.
he  sections  were  de-waxed,  rehydrated  and  subjected
o  epitope  antigen  retrieval  (20  min,  94 ◦C)  with  Target
etrieval  Solution  Low  pH  50x  Dako  EnvisionTM Flex  in  a  pre-
reatment  module  PTlink  (Dako,  Model  PT  10130).  Primary
olyclonal  rabbit  antibody  Pan-Actin  (Cell  Signalling  ref.:
968)  was  incubated  overnight  at  dilution  1:200.  Appendix
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was  used  as  positive  control.  For  negative  control,  primary
antibody  was  omitted  during  the  staining.  Endogenous  per-
oxidise  was  blocked  with  2%  H2O2 in  absolute  methanol  for
10  min.  Sections  were  counterstained  with  Mayer’s  haema-
toxylin.
The  haematoxylin--eosin  slides  were  evaluated  blindly
by  an  experienced  pathologist  and  graded  for  steatosis  and
necro-inﬂammation  as  0  (absent),  1  (sparse  or  mild,  focal),
2  (noticeable)  and  3  (severe)  and  hepatocyte  ballooning
was  graded  as  0  (absent),  1  (few  ballooned  cells),  and  2
(prominent).  Fibrosis  was  quantiﬁed  by  histomorphometric
analysis  of  Sirius  Red  stained  slides,  using  a  digital  camera
(DFC  320,  Leica,  Germany)  coupled  to  a  bright  ﬁeld  micro-
scope  (DM4000,  Leica,  Germany).  Three  randomly  selected
ﬁelds  (10×  magniﬁcation)  of  Sirius  Red-stained  slides  (5-mm
sections)  were  evaluated  at  a  ﬁnal  magniﬁcation  of  100×.
Images  were  analyzed  using  the  LAS  Image  Analysis  from  LAS
-- Leica  Application  Suite  software.  Using  the  ‘Image’  tool
window,  images  were  prepared  for  analysis  using  the  ‘Adjust
contrast’  tool  to  optimize  contrast  and  the  ‘Threshold’  func-
tion  to  select  speciﬁc  signal.  Results  were  measured  in  terms
of  %  area  occupied  by  speciﬁc  staining.19
The  same  method  of  histomorphometric  analysis  was
used  to  quantify  activated  stellate  cells.  SMA-positive  cells
were  evaluated  in  six  ﬁelds  per  specimen,  which  were  ran-
domly  selected  at  200× magniﬁcation.
2.7.  Gut  microbiota
Constituents  of  cecal  microbiota  were  quantiﬁed  using  Fluo-
rescence  in  situ  hybridization  (FISH),  targeting  the  phyla  Fir-
micutes  (Staphylococcus,  Enterococcus, L.  casei/paracasei,
L.  plantarum, Clostridium, Leuconostoc, Pediococcus,
Bacilleacea  and  Streptococcus),  Proteobacteria  (Enterobac-
teriacea),  Fusobacteria  (Fusobacterium),  Actinobacteria
(Propionibacterium  and  Biﬁdobacterium)  and  Bacteroidetes
(Bacteroides).
2.8.  Choosing  and  preparing  probes
Fourteen  probes  of  16S  rRNA-targeted  oligonucleotide
probes  were  designed,  validated  and  used  to  quantify
predominant  bacterial  groups  (SABiosciences  Corporation,
USA).
Sample  preparation  and  ﬁxation:  Faeces  samples  were
weighed  and  diluted  in  distillate  water  (1:10,000).  One
microlitre  of  each  dilution  was  placed  in  slides  previously
washed  with  70%  ethanol.  After  that,  all  samples  were
ﬁxed  by  adding  1  l  of  4%  paraformaldehyde  (Sigma--Aldrich,
Sintra-Portugal)  at  room  temperature  for  20  min  and  washed
in  3×  PBS  solution  by  2  min,  then  repeated  two  more
times.  Permeabilization: Treatment  with  0.05%  (p/v)  of
SDS  (sodium  dodecyl  sulphate)  for  20  min  and  proteinase  K
(Sigma--Aldrich,  Sintra-Portugal)  (Cf  =  10  g/mL)  for  10  min.
Denaturation  and  hybridization: The  probes  (200  ng/L) and
samples  were  simultaneous  denaturated  in  a  bath  at  80 ◦C
for  3  min  and  the  hybridization  was  at  42 ◦C  for  4  h.  Washes:
After  the  hybridization,  slides  were  immersed  in  0.01×
SSC  (saline-sodium  citrate)  and  BT/BSA  (Sigma--Aldrich,
Sintra-Portugal)  solutions  for  10  min  each  according  the
temperature  (Table  1).  DNA  colouration  and  observation:
a
a
w
t135
NA  was  labelled  with  DAPI  (4,6-Diamino-2  Phenylindole;
16H15N5.2HCl-Vector  Laboratories)  (1  mg/ml).  The  slides
ere  observed  in  a  ﬂuorescent  microscopy  Zeiss  Axiovert
00M.  This  microscopy  had  simple  ﬁlters  that  allowed  to  see
eparated  the  CY3,  Texas  Red,  CY5,  FITC  and  Paciﬁc  Blue
nd  DAPI  ﬂuorochromes,  through  the  Plan-Neoﬂuar  100×
mmersion  objective.
After  the  bacteria’s  identiﬁcation,  pictures  were  taken
or  each  sample.  Using  a  MATLAB  program,  and  entering  into
ccount  the  weight,  dilution  of  each  faeces  sample  used  in
he  assay,  as  well  the  picture  area,  total  of  each  bacteria
as  quantiﬁed.20,21
.9.  Statistical  analysis
eneral  descriptive  statistics  used  all  available  samples.
acterial  variations  were  considered  only  for  values  greater
han  2.0  (2×  SD/mean)  in  at  least  one  of  the  groups.
Bacteria  in  which  the  variations  in  all  groups  were  lower
han  this  value,  were  not  considered.  Results  from  dif-
erent  groups  were  compared  using  the  Student’s  t  test
r  Kruskal--Wallis  non-parametric  ANOVA.  Values  of  p  < 0.05
ere  considered  statistically  signiﬁcant.  All  statistical  anal-
sis  was  performed  using  SPSS  statistics  (version  21).
.  Results
.1.  Body  and  liver  weight
ll  mice  had  a  body  weight  increase  at  each  time-point
uring  the  study,  but  no  signiﬁcant  differences  were  found
etween  the  study  groups.  However,  both  HFCD  groups
howed  at  18  weeks  an  increased  liver  weight  when  com-
ared  with  CD  group,  as  shown  in  Table  2.  The  addition  of
ynb  did  not  abrogate  this  increase  in  liver  weight  observed
n  mice  undergoing  HFCD  diet.
.2.  Liver  histology
ontrol  mice  that  were  given  chow  diet,  had  normal  liv-
rs  throughout  the  entire  study  (Fig.  1).  On  the  opposite,  all
ice  undergoing  the  HFCD  diet  developed  aspects  of  steato-
epatitis,  including  steatosis,  inﬂammation,  ballooning  and
brosis.  Consequently,  the  degree  of  steatosis,  inﬂamma-
ion,  ballooning  and  pericellular  ﬁbrosis  was  signiﬁcantly
igher  (p  <  0.05)  in  both  HFCD  groups  than  CD  (where  only
ild  lobular  inﬂammation  was  seen);  the  use  of  Synb  did  not
brogate  the  severity  of  these  histological  parameters  at  any
ime  point,  as  observed  and  scored  using  conventional  H&E
tained  slides  (Fig.  1) (Table  3).
However,  when  evaluating  ﬁbrosis  using  Sirius  Red,  it  was
ound  that  the  percentage  of  ﬁbrosis  at  6  and  18  weeks  was
igniﬁcantly  decreased  with  the  addition  of  Synb,  as  seen  in
able  4,  p  =  0.001  at  6  weeks,  and  p  =  0.04  at  18  weeks.
Activation  of  stellate  cells  was  evaluated  using  -SMA
ntibody.  As  seen  in  Fig.  2, signiﬁcant  increases  were  found
t  week  18  in  mice  undergoing  HFCD  diet  when  comparing
ith  CD,  p  =  0.007.  This  increase  was  markedly  abrogated  by
he  addition  of  Synbiotic  2000®Forte  to  HFCD  diet,  p  =  0.003.
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Table  1  Probes  sequence,  ﬂurochomes  and  hybridization  temperature.
Identiﬁcation  Sequence  Fluorochome  Hybridization  temp.  (◦C)
Pediococcus  pentosaceus  5′-GCC  ATC  TTT  TAA  AAG  AAA  ACC  ATG  C-3′ Cy3 48 ◦C
Leuconostoc  mesenteroides  5′-TTT  GTG  TCA  TGC  GAC  ACT  AAG  TTT  T-3′ Cy5
Lactobacillus  casei/paracasei  5′-CGT  TCC  ATG  TTG  AAT  CTC  GGT  G-3′ Paciﬁc  Blue
Bacillaceae 5′-CGT  CCA  TTR  NKG  AAG  ATT  CCC  TA-3′ FITC
Fusobacterium  5′-CGT  CCA  TTR  NKG  AAG  ATT  CCC  TA-3′ Taxas  Red 53 ◦C
Staphylococcus  5′-CNC  CGA  AGR  GGD  ARN  YTC  TAT  CTC  TAG  A-3′ Cy3
Enterococcus  5′-TTT  CCA  AGT  GTT  ATC  CCY  YNC  TGA  NG-3′ Cy5
Bacteroides  5′-CCT  TCA  CGC  TAC  TTG  GCT  GGT  TCA  G-3′ Paciﬁc  Blue
Enterobacteriacea  5′-GAC  NTY  ATG  CGG  TAT  TAG  CYA  CCG-3′ FITC
Propionibacterium  5′-TTG  ACC  CCG  GCG  GTC  TCC  ACT  GAG  TCC-3′ Texas  Red 58 ◦C
Clostridium 5′-GTG  GCT  TCC  TCC  NHN  GGT  ACC  GTC  ATT  ATC-3′ Cy3
Lactobacillus  plantarum  5′-TGT  TAT  CCC  CCG  CTT  CTG  GGC  AGG  TT-3′ Cy5
Biﬁdobacterium  5′-CTG  ATA  GGA  CGC  GAC  CCC  ATC  NCA-3′ Paciﬁc  Blue
Streptococcus  5′-ACC  AAC  TAG  CTA  ATA  CAN  CGC  AGG  TNC  ATC  T-3′ FITC
Table  2  Body  weight  and  liver  weight  at  different  time  points.
Group  Week Body  weight  (g) Mean  weight  gain Liver  weight  (g) Liver/total  body  weight  ratio  (%)
CD 0  18.6
6  23.4  ±  1.6  5.0  0.9  ±  0.1  3.8
18 25.6  ±  1.7  7.2  1.2  ±  0.1  4.7
HFCD 0 18.8
6  21.6  ±  0.7  2.8  1  ±  0.1  4.6
18 27.9  ±  3.0  9.1  2  ±  0.2* 7.1*
HFCD  +  Synb 0  18.9
6  23.4  ±  1.6  4.5  1.6  ±  1.3  6.8
18 25.1  ±  0.4 6.2  1.7  ±  0.1* 6.7*
CD: chow diet; HFCD: high-fat choline deﬁcient diet; Synb: synbiotic.
* Statistically signiﬁcant, p < 0.01.
At 18 weeks, liver weight as well as liver/body weight ratio was signiﬁcant higher in either HFCD or HFCD + Synb diet than CD diet,
p < 0.01.
CD HFCD
6 
W
e
e
ks
18
 W
e
e
ks
 HFCD + Synb
Figure  1  H&E  stained  liver  sections  20×  from  representative  mice  fed  with  CD  diet  (CD)  and  mice  fed  high-fat  choline-deﬁcient
d
a
tiet (HFCD)  diet  or  high-fat  choline-deﬁcient  diet  plus  Synbiotic,  as
spects of  steatohepatits  at  6  and  18  weeks  that  were  not  present  in  
hese aspects. detailed  in  Methods.  HFCD  diet  and  HFCD  diet  +  Synb  showed
mice  undergoing  CD  diet.  The  addition  of  Synb  did  not  abrogate
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Table  3  Mean  histological  scores  for  each  time  point  according  to  group  (H&E).
Group  Week  Steatosis  Intralobular  inﬂammation  Ballooning  Pericelular  ﬁbrosis
CD 6  0  0.75  0  0
18 0  0.6  0  0
HFCD 6 3  3  1  1.6
18 2.4  2.6  2  3
HFCD +  Synb 6  3  2  2  1
18 3  2.2  2  1.6
Signiﬁcant differences in mean scores (p < 0.05), at each time point for steatosis, intralobular inﬂammation, ballooning and pericellular
ﬁbrosis between CD vs HFCD and HFCD + Synb. No differences between
CD
HFCD
Weeks 18Weeks 6
0
2
4
6
8
10
12
HFCD+Synb
Figure  2  Percentage  of  -SMA  positive  cells  (activated  stel-
late cells).  Signiﬁcant  increases  were  found  at  week  18  in  mice
undergoing  HFCD  diet  when  comparing  with  CD,  p  =  0.007.  This
increase  was  markedly  abrogated  by  the  addition  of  Synb  to
HFCD diet,  p  =  0.003.
Table  4  Percentage  ﬁbrosis  (Sirius  RED).
Group  6  weeks  18  weeks
CD  1.1  ±  0.2  0.6  ±  0.06
HFCD 7.4  ±  2.9  10.7  ±  2.6
HFCD +  Synb  3.2  ±  1.0  6.3  ±  2.3
6 weeks: CD vs HFCD, p = 0.001; HFCD vs HFCD + Synb, p = 0.001.
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Regarding  Leuconostoc  and  Pediococcus  an  increase  at
week  6  (23.6)  and  (14.7)  and  a  decrease  at  week  18  (−2.3)18 weeks: CD vs HFCD, p = 0.000; HFCD vs HFCD + Synb, p = 0.04.
3.3.  LPS  and  Gram-negative  bacteria
At  week  6,  there  was  a  signiﬁcant  increase  in  Gram-negative
bacteria  and  LPS  levels  in  the  two  HFCD  diet  groups,  when
comparing  with  CD  diet,  not  abrogated  by  the  addition  of
Synbiotic  2000®Forte.  However,  at  week  18,  although  levels
of  LPS  and  Gram-negative  bacteria  continued  to  increase  in
HFCD  group,  the  addition  of  Synbiotic  2000®Forte  abrogated
this  effect,  as  shown  in  Fig.  3.
3.4.  Gut  microbiotaData  from  microbiota  will  be  presented  at  the  phylum  and
species  levels.
a
t HFCD and HFCD + Synb.
.5.  Phylum  level  (Table  5)
n  HFCD  versus  CD,  there  was  an  increase  of  Proteobacteria
t  week  6  (3.3)  and  at  week  18  (7.5)  and  Fusobacteria  (2.8)
nd  (10.2)  respectively;  concerning  Actinobacteria  there
as  a  decrease  at  week  18  (−6.7).  Regarding  Firmicutes  and
acteroidetes  no  major  changes  were  observed  at  the  same
ime  course.
In  HFCD  +  Synb  vs  CD,  there  was  an  increase  of  Pro-
eobacteria  at  week  6  (5.3)  and  a  decrease  at  week  18
−3.9).  Fusobacteria  had  a  huge  increase  at  week  6  (41.7),
nd  at  week  18  (5.8).  Regarding  Bacteroidetes  there  was  a
ecrease  at  week  6  (−4.6).  Actinobacteria  had  a  decrease  at
eek  18  (−7.6).  No  major  changes  at  Firmicutes  were  found
oth  times.  In  HFCD  + Synb  vs  HFCD,  no  changes  found  at
roteobacteria  and  Actinobacteria,  an  increase  of  Fusobac-
eria  at  week  6  (15.1),  a decrease  of  Bacteroidetes  at  week
 (−5.0),  and  an  increase  of  Firmicutes  at  week  6  (4.2)  and
ecrease  at  week  18  (−2.3).
.6.  Species  level  (Table  6)
n  the  species  level,  comparing  HFCD  versus  CD,  there  is  an
ncrease  of  Enterobacteriaceae  (2.5  and  7.5)  and  Fusobac-
erium  (2.8  and  10.2)  at  6  and  18  weeks,  while  there  is
 decrease  of  Biﬁdobacterium  (−47.7)  and  Streptococcus
−5.0)  at  week  18.  A  decrease  of  Leuconostoc  was  found  at
oth  times  (−14.9  and  −4.6),  a  decrease  of  Pediococcus  at
eek  6  (−10.0)  and  an  increase  at  week  18  (4.2),  a  decrease
f  L.  casei  at  both  times  (−8.7  and  −2.7)  and  a  decrease  of
.  plantarum  only  at  week  18  (−6.6).
Regarding  HFCD  +  Synb  versus  CD  there  is  an  increase  of
nterobacteriaceae  (5.3  and  3.9)  and  Fusobacterium  (41.7
nd  5.8)  a  decrease  of  Biﬁdobacterium  (−8.8  and  −14.3)
t  both  times,  Streptococcus  and  Leuconostoc  a  decrease  at
eek  18  (−21.8)  and  (−56.4).  Concerning  L.  casei  there  is  a
ecrease  at  both  times  (−8.6  and  −2.9)  and  a decrease  of
.  plantarum  only  at  week  18  (−6.5).
When  comparing  HFCD  +  Synb  versus  HFCD,  no  changes  in
nterobacteriaceae  were  found  at  both  times,  an  increase
f  Fusobacterium  at  week  6  (15.1)  a  decrease  of  Biﬁdobac-
erium  at  week  6  (−14.6)  and  an  increase  at  week  18  (3.3),
 decrease  of  Streptococcus  at  both  time  (−2.2  and  −4.4).nd  (−2.8)  respectively.  Concerning  L.  casei  and  L.  plan-
arum,  no  changes  found  at  both  times.
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Table  5  Phylum  values.
Firmicutes  Proteobacteria  Actinobacteria  Bacteroides  Fusobacteria
HFCD  vs  CD  (6  wk)  −1.7  3.3  1.1  1.1  2.8
HFCD vs  CD  (18  wk)  1.6  7.5  −6.7  1  10.2
HFCD +  Synb  vs  CD  (6  wk)  2.4  5.3  1.1  −4.6  41.7
HFCD +  Synb  vs  CD  (18  wk)  −1.4  −3.9  −7.6  −1.2  5.8
HFCD +  Synb  vs  HFCD  (6  wk)  4.2  2.1  1  −5  15.1
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Bacterial variations were considered only for values greater than 
There  was  no  change  in  species  not  mentioned  (Entero-
occus,  Clostridium  and  Propionibacterium).
. Discussion
he  main  ﬁnding  of  the  present  study  is  that  a  symbiotic  was
ble  to  reduce  HFCD  diet-induced  ﬁbrosis,  when  evaluated
ither  by  the  measurement  of  ﬁbrosis  with  Sirius  Red  or  the
ercentage  of  activated  stellate  cells.  Simultaneously,  there
as  evidence  that  the  addition  of  the  Synbiotic  2000®Forte
brogated  the  HFCD-associated  increase  in  the  abundance
f  Gram-bacteria  in  the  stools,  this  effect,  simultaneously
educing  serum  levels  of  LPS.  These  results  reinforce  the
oncept  that  increased  endotoxemia  is  one  of  the  main
echanisms  through  which  microbiota  composition  asso-
iates  with  the  presence  and  severity  of  NAFLD,  as  previously
hown.22--24 In  fact,  human  studies  were  able  to  show  ele-
ated  serum  endotoxin  levels  in  patients  with  NAFLD,  when
ompared  to  controls,25 furthermore  elevated  in  patients
ith  NASH.26
The  diet  mice  model  used  in  the  present  study  resulted  in
 full-blown  picture  of  steatohepatitis.  The  high-fat  choline
eﬁcient  diet  model  was  chosen  in  order  to  have  more  simi-
arities  with  the  human  phenotype  of  NASH.  The  more  classic
ethionine  choline  deﬁcient  diet  model  was  avoided,  since
hose  mice  in  fact  lose  weight,  in  opposition  to  human  NASH.
lso,  we  did  not  use  high-fat  diet  model,  since  although
hey  get  steatosis,  NASH  does  not  systematically  develop,
hus  creating  difﬁculties  in  the  evaluation  of  an  interven-
ion.  As  intervention,  the  use  of  a  Synbiotic  was  chosen
nstead  of  a  probiotic  alone,  due  to  the  potential  advantage
m
o
t
o
12
CD 6 CD 18
LP
S 
(ng
/m
L)
HFCD 6 HFCD
LPS Gram –
10
8
6
4
2
0
igure  3  LPS  levels  (ng/ml),  and  Gram-negative  bacteria.  At  wee
f Gram-negative  bacteria,  in  the  two  HFCD  diet  groups,  when  com
eek 18,  although  levels  of  LPS  and  number  of  Gram-negative  bacte
artially abrogated  this  effect.−1.1  −1.2  −1.8
2×  SD/mean).
f  improving  the  viability  of  the  probiotic.27 In  human  stud-
es,  this  particular  Synbiotic  (Forte  2000)  has  shown  to
nduce  lower  intestinal  permeability  and  fewer  infections
n  trauma  patients,28 but  had  no  signiﬁcant  impact  on  the
ncidence  of  VAP  in  critically  ill  patients.29
The  use  of  the  Synbiotic  2000®Forte  had  no  effect  in
brogating  steatosis  or  necro-inﬂammation  induced  by  the
FCD  diet,  but  was  able  to  reduce  the  degree  of  ﬁbrosis,
ith  a  good  correlation  with  a  decrease  in  Gram-  bacteria
nd  LPS.  A  previous  study  in  rats  had  shown  that  a  high-
at  diet  (45%  fat)  was  associated  with  a  decrease  in  total
acterial  density  and  an  increase  in  the  relative  proportion
f  Bacteroidales  and  Clostridiales, which  may  induce  LPS
levation,  gut  inﬂammation  and  TLR4  activation.30,31 In  the
resent  study,  using  a  less  fat  diet  (35%),  but  54%  trans-
atty  acid  enriched,  we  have  not  observed  a  huge  increase
n  Firmicutes  and  a decrease  of  Bacteroidetes,32 but  only  a
mall  effect  (increase  of  Firmicutes  only  at  week  18  (1.6)  in
opulation  ratio  HFCD  versus  CD  group,  and  no  changes  in
acteroidetes).  Regarding  Proteobacteria  we  observed  an
ncrease,  that  latter  being  reduced  by  the  addition  of  the
ynbiotic.  The  reduction  in  Gram-bacteria  may  be  due  to
ncreased  production  of  short-chain  fatty  acids  (SCFA),  dur-
ng  the  anaerobic  metabolism  of  the  prebiotic  associated
arbohydrates.  In  fact,  SCFA  are  nonspeciﬁc  antimicrobial
ubstances  that  decrease  pH,  inhibiting  growth  of  a  wide
ange  of  Gram-bacteria.33
It  is  of  note,  that  in  one  recent  study  where  human
icrobiota  was  studied,  it  was  found  that  the  abundance
f  Proteobacteria  increased  from  the  healthy  group  to
he  obese  group  and  then  to  the  NASH  group,  being  the
nly  abundant  phylum  exhibiting  a signiﬁcant  difference
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k  6,  there  was  a  signiﬁcant  increase  in  LPS  levels  and  number
paring  with  CD  diet,  not  abrogated  by  the  addition  of  Synb.  At
ria  continued  to  increase  in  HFCD  group,  the  addition  of  Synb
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etween  the  latter  two  groups.34 It  was  furthermore  shown
hat  the  Proteobacteria  were  mostly  Enterobacteria,  and
mong  those,  mostly  Escherichia  coli  that  are  ethanol  pro-
ucers;  the  authors  also  found  NASH  patients  to  have  more
levated  blood  ethanol  concentrations,34 similar  to  previ-
us  studies.35,36 The  increase  of  Biﬁdobacterium  at  week  18,
ay  be  responsible  for  the  beneﬁcial  effect  of  the  symbiotic;
n  fact  it  has  been  previously  shown  that  an  increase  in  Biﬁ-
obacterium  associates  with  an  anti-inﬂammatory  effect.37
Previous  studies  showed  that  obesity  associates  with
 low-grade  chronic  inﬂammation  that  contributes  to  the
evelopment  of  insulin  resistance,  type  2  diabetes  and  car-
iovascular  diseases.38,39 In  our  HFCD  diet  model,  mice  did
ot  in  fact  get  obese,  but  had  all  the  features  of  steato-
epatitis  and  an  increase  in  LPS  suggesting  an  on-going
ow-grade  inﬂammation.  The  mechanisms  explaining  the
igh-fat  induced,  increase  in  endotoxin  levels,  may  relate
o  the  increase  in  Gram-bacteria,  but  it  is  also  possible
hat  high-fat  feeding  might  induce  an  increase  in  intestinal
ermeability.  In  fact,  Stenman  and  col,  found  that  high-fat
eeding  in  mice  signiﬁcantly  increased  intestinal  permeabil-
ty  of  the  jejunum  and  colon,  associating  with  a  decreased
roportion  of  faecal  UDCA  and  increased  FXR  expression.40
here  is  also  evidence,  that  high-fat  diet  induces  hyper
eactivity  against  low-dose  LPS,  through  an  up-regulation
f  CD14  by  leptin-mediated  signalling.41
The  observation  of  increased  activation  of  hepatic  stel-
ate  cells  (HSC),  and  increased  ﬁbrosis,  is  probably  due
o  LPS-mediated  signalling  through  toll-like  receptor  4
TLR4),42 which  has  been  identiﬁed  as  a  ﬁbrogenic  signal
n  HSC.43 It  is  however  intriguing  that  we  were  not  able  to
nd  any  reduction  in  the  degree  of  necro-inﬂammation  in
ice  supplemented  with  the  synbiotic.  It  is  possible  that
onventional  histology  was  not  sensitive  enough  to  detect
inor  changes  in  necro-inﬂammation,  since  also  regarding
brosis  degree,  no  signiﬁcant  changes  were  changes  were
ound  in  conventional  histology,  although  using  either  Sir-
us  Red,  or  alpha  smooth-muscle  immunohistochemistry  to
etect  ﬁbrosis  or  stellate  cell  activation,  a  signiﬁcant  reduc-
ion  was  found.  It  is  possible  that  a  more  sensitive  approach,
ventually  using  immunohistochemistry  to  quantify  inﬂam-
atory  cells  (macrophages,  polymorphonuclear  leukocytes,
nd  lymphocyte  subpopulations)  could  clarify  the  severity
f  cell-death  and  associated  inﬂammation.
The  present  ﬁndings  reinforce  the  rational  for  modulat-
ng  microbiota  in  the  setting  of  obesity  and  NAFLD.  In  fact,
here  are  a  large  number  of  studies  evaluating  the  effect  of
robiotics  in  murine  models  and  in  humans  with  NAFLD,  as
eviewed.44,45 However,  we  are  still  missing  well-designed
rials,  to  evaluate  the  effect  of  mixtures  of  pre  and  pro-
iotics  in  NAFLD  that  are  very  difﬁcult  to  accomplish.  The
ifﬁculty  results  from  the  slow  and  rather  unpredictable
ourse  of  NAFLD,  but  also  to  the  difﬁculty  of  assuring  the
tability  and  the  amount  of  the  pre  and  probiotics  prepara-
ions.
.  Conclusionso,  in  summary  we  found  that  mice  undergoing  a  high-fat
holine  deﬁcient  diet  develop  steatohepatitis,  while  simul-
aneously  leading  to  microbial  dysbiosis,  with  increased
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240  
ndotoxemia  and  liver  ﬁbrosis,  this  effect  being  at  least
artially  corrected  with  the  use  a  of  a  mixture  of  pre  and
robiotics.  The  prospect  for  using  these  substances  in  clin-
cal  practice,  although  attractive,  is  not  yet  demonstrated
n  good  clinical  trials  in  humans.  Also,  we  need  to  be  aware
hat  in  this  study,  the  Synbiotic  2000®Forte  intervention  was
one  simultaneously  with  the  diet.  In  practice,  we  usually
ntervene  when  the  situation  is  already  established,  what
an  make  a  large  difference.
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